vs
Apellis Pharmaceuticals, Inc.（APLS）与loanDepot, Inc.（LDI）财务数据对比。点击上方公司名可切换其他公司
loanDepot, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$310.3M vs $199.9M），loanDepot, Inc.净利率更高（-7.2% vs -29.5%，领先22.2%），loanDepot, Inc.同比增速更快（20.5% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-648.0M），过去两年loanDepot, Inc.的营收复合增速更高（18.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
loanDepot, Inc.是一家总部位于美国加利福尼亚州欧文市的非银行控股公司，主营抵押贷款及其他非抵押类贷款产品的销售业务，是美国市场上颇具规模的消费信贷服务提供商。
APLS vs LDI — 直观对比
营收规模更大
LDI
是对方的1.6倍
$199.9M
营收增速更快
LDI
高出26.4%
-5.9%
净利率更高
LDI
高出22.2%
-29.5%
自由现金流更多
APLS
多$633.7M
$-648.0M
两年增速更快
LDI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $310.3M |
| 净利润 | $-59.0M | $-22.5M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -10.3% |
| 净利率 | -29.5% | -7.2% |
| 营收同比 | -5.9% | 20.5% |
| 净利润同比 | -62.2% | 32.4% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLDI
| Q4 25 | $199.9M | $310.3M | ||
| Q3 25 | $458.6M | $323.3M | ||
| Q2 25 | $178.5M | $282.5M | ||
| Q1 25 | $166.8M | $273.6M | ||
| Q4 24 | $212.5M | $257.5M | ||
| Q3 24 | $196.8M | $314.6M | ||
| Q2 24 | $199.7M | $265.4M | ||
| Q1 24 | $172.3M | $222.8M |
净利润APLSLDI
| Q4 25 | $-59.0M | $-22.5M | ||
| Q3 25 | $215.7M | $-4.9M | ||
| Q2 25 | $-42.2M | $-13.4M | ||
| Q1 25 | $-92.2M | $-21.9M | ||
| Q4 24 | $-36.4M | $-33.2M | ||
| Q3 24 | $-57.4M | $1.4M | ||
| Q2 24 | $-37.7M | $-32.2M | ||
| Q1 24 | $-66.4M | $-34.3M |
营业利润率APLSLDI
| Q4 25 | -25.6% | -10.3% | ||
| Q3 25 | 48.7% | -3.2% | ||
| Q2 25 | -18.6% | -11.4% | ||
| Q1 25 | -50.0% | -16.8% | ||
| Q4 24 | -12.3% | -32.7% | ||
| Q3 24 | -24.0% | 1.1% | ||
| Q2 24 | -14.7% | -29.1% | ||
| Q1 24 | -36.0% | -38.2% |
净利率APLSLDI
| Q4 25 | -29.5% | -7.2% | ||
| Q3 25 | 47.0% | -1.5% | ||
| Q2 25 | -23.6% | -4.7% | ||
| Q1 25 | -55.3% | -8.0% | ||
| Q4 24 | -17.1% | -12.9% | ||
| Q3 24 | -29.2% | 0.4% | ||
| Q2 24 | -18.9% | -12.1% | ||
| Q1 24 | -38.5% | -15.4% |
每股收益（稀释后）APLSLDI
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $-0.18 | ||
| Q1 24 | $-0.54 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $337.2M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $370.1M | $386.0M |
| 总资产 | $1.1B | $6.9B |
| 负债/权益比越低杠杆越低 | — | 5.44× |
8季度趋势，按日历期对齐
现金及短期投资APLSLDI
| Q4 25 | $466.2M | $337.2M | ||
| Q3 25 | $479.2M | $459.2M | ||
| Q2 25 | $370.0M | $408.6M | ||
| Q1 25 | $358.4M | $371.5M | ||
| Q4 24 | $411.3M | $421.6M | ||
| Q3 24 | $396.9M | $483.0M | ||
| Q2 24 | $360.1M | $533.2M | ||
| Q1 24 | $325.9M | $603.7M |
总债务APLSLDI
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | $93.1M | $2.3B |
股东权益APLSLDI
| Q4 25 | $370.1M | $386.0M | ||
| Q3 25 | $401.2M | $433.3M | ||
| Q2 25 | $156.3M | $439.1M | ||
| Q1 25 | $164.2M | $469.3M | ||
| Q4 24 | $228.5M | $506.6M | ||
| Q3 24 | $237.1M | $592.0M | ||
| Q2 24 | $264.3M | $578.9M | ||
| Q1 24 | $266.7M | $637.3M |
总资产APLSLDI
| Q4 25 | $1.1B | $6.9B | ||
| Q3 25 | $1.1B | $6.2B | ||
| Q2 25 | $821.4M | $6.2B | ||
| Q1 25 | $807.3M | $6.4B | ||
| Q4 24 | $885.1M | $6.3B | ||
| Q3 24 | $901.9M | $6.4B | ||
| Q2 24 | $904.5M | $5.9B | ||
| Q1 24 | $831.9M | $6.2B |
负债/权益比APLSLDI
| Q4 25 | — | 5.44× | ||
| Q3 25 | — | 4.83× | ||
| Q2 25 | — | 4.70× | ||
| Q1 25 | — | 4.30× | ||
| Q4 24 | — | 4.00× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | 3.41× | ||
| Q1 24 | 0.35× | 3.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-638.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-648.0M |
| 自由现金流率自由现金流/营收 | -7.1% | -208.9% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-734.6M |
8季度趋势，按日历期对齐
经营现金流APLSLDI
| Q4 25 | $-14.2M | $-638.7M | ||
| Q3 25 | $108.5M | $43.4M | ||
| Q2 25 | $4.4M | $67.6M | ||
| Q1 25 | $-53.4M | $-179.9M | ||
| Q4 24 | $19.4M | $47.7M | ||
| Q3 24 | $34.1M | $-349.2M | ||
| Q2 24 | $-8.3M | $-278.3M | ||
| Q1 24 | $-133.0M | $-278.5M |
自由现金流APLSLDI
| Q4 25 | $-14.3M | $-648.0M | ||
| Q3 25 | $108.3M | $38.7M | ||
| Q2 25 | $4.4M | $61.4M | ||
| Q1 25 | $-53.4M | $-186.7M | ||
| Q4 24 | $19.3M | $40.8M | ||
| Q3 24 | — | $-356.4M | ||
| Q2 24 | $-8.4M | $-285.7M | ||
| Q1 24 | $-133.3M | $-283.3M |
自由现金流率APLSLDI
| Q4 25 | -7.1% | -208.9% | ||
| Q3 25 | 23.6% | 12.0% | ||
| Q2 25 | 2.5% | 21.7% | ||
| Q1 25 | -32.0% | -68.2% | ||
| Q4 24 | 9.1% | 15.8% | ||
| Q3 24 | — | -113.3% | ||
| Q2 24 | -4.2% | -107.7% | ||
| Q1 24 | -77.3% | -127.2% |
资本支出强度APLSLDI
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.0% | 2.5% | ||
| Q4 24 | 0.0% | 2.7% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 2.8% | ||
| Q1 24 | 0.2% | 2.1% |
现金转化率APLSLDI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -255.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LDI
暂无分部数据
